🤔 Could Defeat Parkinson’s

Post a Comment
A novel treatment

Neurological diseases like Parkinson's and dementia are some of the most difficult to treat.

While we've come a long way, our understanding pales in comparison with most deteriorative biological diseases.

We know how to treat and prevent heart disease.

But when it comes to the brain, we're still in the dark ages.

While it's true there are hundreds, if not thousands, of companies trying to tackle today's problems, Inhibikase Therapeutics, Inc. (NASDAQ: IKT) has a unique solution to the problem.

Rather than trying to reimagine the problem, they focus on reengineering, taking what works elsewhere and applying it to their research and development.

And for traders, there's plenty of price action around these promotions.

Inhibikase Therapeutics, Inc. (NASDAQ: IKT)

  • 1-month trading range: $0.5200 - $0.9345
  • Typical average daily volume: ~320,000
  • Float: 22.67 million

Inhibikase Therapeutics' Business

Not all drugs are spun from thin air.

Inhibikase starts with currently marketed or clinically evaluated small molecule drugs that target Central Nervous System (CNS) or non-CNS diseases.

Then, they use the preexisting chemical entities as a template to pursue clinically validated targets to create products that treat neurodegenerative diseases.

Essentially, they take current drugs and make them better.


Source: Inhibikase Website

The company's trademarked Re-engineering Approach with Metabolism Preserved (RAMP™) is the secret sauce that helps them develop these novel drugs.

For neurological diseases, the company focuses on developing a new class of protein kinase inhibitors for CNS diseases sensitive to the treatment.

In 2021, the company commenced its clinical trials for its IkT-148009, a small molecule Abelson Tyrosine Kinase inhibitor, which it believes can treat Parkinson's and the gastrointestinal it causes.

The company's current pipeline includes some exciting updates:O5MVuZWZ1R_rNPETo4tKprF9fgpiPcFGhM3yjB7r62qy-Awwuaud7TNA55QxUso9zfliSfclxTS6QooYwMjIJ0ybYC2GeTiJy218lSutVwD7YrkP_ZTuJ_Ybpt7WG8nbCip_ypB3lA-qpqe3uLf1aLU

On March 8, the FDA lifted its full clinical hold on Inhibikase's IkT-148009 for Multiple System Atrophy, allowing them to continue with Phase II clinical trials.

Phase II evaluates the safety, tolerability, and efficacy of the drug.

It's worth noting the stock jumped 35% overnight on the news, although it closed near the days lows.

Nonetheless, that day saw nearly 2 million shares traded.

However, when the FDA lifted its hold on the general Parkinson's trials on January 25, the stock, which had already jumped almost 30% in the two days prior, popped another 26% on nearly 9 million shares of volume, bringing the total gains to almost 65% over three trading days.

To be fair, shares quickly retreated and gave up all the gains within another two days.

Phase IIa began screening patients in Q1 of this year.

While the focus is mainly on neurodegenerative diseases, Inhibiakse also has Orphan Drug Designation (limited use case) from the FDA and is currently in Phase III trials which is expected to be completed in the first half of 2023.

Promoter Activity

I came across two promoters delivering campaigns for IKT.

Both laid out the following as catalysts:

  1. FDA ruling to lift its hold on the Phase II trial for Multiple System Atrophy
  2. Low float
  3. Parkinson's treatment market size will hit over $12 billion within a decade
  4. Strong partnerships with leading research institutions.

The FDA ruling paves the way for the company to continue its progress. After all, when the hold was announced, shares dropped by almost 50% the following day.

And when the hold was lifted, shares ran hard.

Much of the price action will depend on the results from the studies, which should leak out over the next 6-12 months.

Now, I wouldn't call the stock low-float with 22.67 million shares. But it's not heavy either. Let's just go with medium rare.

The market size for Parkinson's treatments is huge. However, that's nothing new, and the company still needs to get its drugs approved.

Collaborations between IKT and leading institutions such as the National Institutes of Health (NIH), the University of California, and the Michael J. Fox Foundation certainly add credibility to the company. But, again, it's nothing that hasn't been known for quite a while.

So, let's talk about one of our favorite topics - money.

Both promoters were hired from 3/2/2023 - 3/17/2023 for a whopping $175,000 each.

That's a lot of money and a lengthy promotion - one of the costliest and longest I've covered to date.

Straight to the Facts

Given the length of the promotion, any news released during this period is likely going to get a lot of eyeballs.

That could quickly translate into a lot of interest in the stock.

While I said many of the other stocks I've covered should be on watchlists for months, this one I would keep a close eye on this through the 17th.

Always at your service,

Baron Von Stocks

P.S. Want instant STOCK alerts on the HOTTEST awareness stocks? Join our free sms list here >>

Disclaimer: Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is not a recommendation nor an offer to buy or sell securities. This newsletter is owned by Red Oak Media Group LLC. Any wording found in this e-mail or disclaimer referencing to "I" or "we" or "our" or "AS" refers to Red Oak Media Group LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices.

Related Posts

There is no other posts in this category.

Post a Comment

Subscribe Our Newsletter